Ecolab Inc.

Christophe Beck said Adjusted EPS grew 11% and organic sales grew 5%, with stable organic gross margin and strong productivity. He also said volumes grew 1%, pricing was 4% in the second quarter and is expected to move to 5% to 6% in the second half, and that second-half organic sales growth should be 6% to 7% with adjusted operating income margin at 19%. Ecolab raised 2026 EPS guidance to $8.05 to $8.25, implying 7% to 10% growth versus last year. Management reiterated a 20% operating income margin target for 2027 and said adjusted EPS growth including CoolIT should accelerate to 12% to 15% over time.

Christophe Beck emphasized that the quarter reflected accelerating execution across the portfolio, with the company shifting toward higher-growth, higher-margin businesses. He highlighted strong momentum in food and beverage, life sciences, digital, pest elimination, and global high-tech, and repeatedly framed the strategy as one of combining pricing discipline, innovation, and a broader integrated platform. His tone was confident and upbeat, with a focus on long-term trajectory, including 5% to 7% organic growth, margin expansion beyond 20%, and an upcoming Investor Day in November.

Scott Kirkland focused on how pricing, commodity costs, and acquisition accounting affect margins. He said the company expects high-single-digit commodity prices for the balance of the year, noted a roughly 60-basis-point gross margin drag from Ovivo on a reported basis, and said CapEx should remain around 7% over the next couple of years because Ecolab is investing ahead of growth in high-tech and life sciences. He also said the CoolIT returns are well above cost of capital, ROIC should grow by at least 100 basis points a year, and organic ROIC is expected to return to pre-acquisition levels by 2028.

Analysts pressed management on whether CoolIT’s amortization would make the 20% operating margin target for 2027 harder to reach; Beck reaffirmed the target and said the second half of 2027 should be even stronger as CoolIT laps. They also asked about high-tech mix and growth assumptions, and Beck said the platform is roughly $1.5 billion annualized, with each of legacy, CoolIT, and Ovivo around $500 million, and reiterated confidence in the $4 billion by 2030 target. Other questions focused on life sciences share gains, CapEx, pricing versus raw material inflation, and pest/digital growth; management said the businesses are still early in their scaling phase but are seeing strong customer adoption and will keep investing ahead of growth.